Novartis plans to file for new Lucentis indication in ROP

Novartis plans to file for new Lucentis indication in ROP

Source: 
Pharmaceutical Business Review
snippet: 

Novartis has unveiled plans to file ex-US for a new indication for Lucentis (ranibizumab) in retinopathy of prematurity (ROP), a rare disease in premature infants.